#United States #Los Angeles #Securities Fraud #Glancy Prongay #Iovance Biotherapeutics

Investors Stand Up: Iovance Biotherapeutics Inc. and the Chance to Lead a Class Action Lawsuit

Investors who faced financial setbacks from their dealings with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have a pivotal opportunity. According to a recent announcement from the law firm Glancy Prongay & Murray LLP, eligible investors can step forward to lead a class action lawsuit concerning securities fraud. This lawsuit claims that the company misled investors over the course of almost a year.

What Led to the Lawsuit?

The class action lawsuit stems from allegations that, between May 9, 2024, and May 8, 2025, the company failed to disclose crucial information related to the performance of its newly authorized treatment center (ATC) program for a drug named Amtagvi. These undisclosed issues include:
1. Delayed Treatment Initiation: Newly authorized treatment centers reportedly faced significant delays in starting patient treatments with Amtagvi.
2. Operational Inefficiencies: There were claims that the company's sales teams and ATCs struggled with identifying and selecting suitable patients for Amtagvi, resulting in increased patient drop-offs.
3. Financial Repercussions: The above challenges led to soaring costs and diminishing revenues, as the ATCs were unable to keep pace with the quantity of manufactured product.
4. Misleading Communications: Due to these dynamics, it is alleged that the positive statements made by company executives regarding Iovance’s business health and operational prospects were flawed and lacked a factual basis.

How Can Investors Participate?

Investors who encountered losses during this specified time are encouraged to act quickly. The deadline to engage as a lead plaintiff in this securities fraud lawsuit is July 14, 2025. Interested parties should reach out to Glancy Prongay & Murray LLP for more information on how to proceed.

Contact information is provided below for those wishing to understand their rights and options regarding the matter:

• - Attorney Contact: Charles Linehan
• - Firm: Glancy Prongay & Murray LLP
• - Address: 1925 Century Park East, Suite 2100, Los Angeles, California 90067
• - Email: 48hCode
• - Phone: 310-201-9150 | Toll-Free: 888-773-9224

Needless to say, this lawsuit carries substantial significance, as it aims not only to hold corporations accountable for transparency and honesty but also offers investors a pathway to recover lost earnings.

Conclusion

For investors who have suffered financial losses while investing in Iovance Biotherapeutics Inc., this class action presents a unique opportunity to address grievances against the company. The implications of this lawsuit extend beyond individual recovery, resonating on broader grounds about corporate responsibility and investor rights. If you believe you qualify, do not miss this chance to take a stand. Further updates can be found on relevant legal and financial news platforms.

• ---

Stay tuned for updates, and remember, timely action is essential in negotiations such as these. For continuous updates on the unfolding developments in this case and other financial news, follow various platforms to stay informed.